米国市場におけるジェネリック医薬品の侵食パターン

Abstract

Introduction

With an estimated $51 billion of branded drugs coming off patent between 2006 and 2011, both U.S. government insurance plans and private, third-party payers will promote increased use of generics in the future. In a data-rich report that employs analyses of 34 branded drugs facing generics competition between January 2002 and December 2006, we highlight the most effective strategies employed by pharmaceutical companies in their effort to ward off the threat of generics competition.

Get the Answers You Need to Shape Your Strategy:

• Several factors determine how quickly a branded product loses market share. Which of these factors is particularly likely to lead to big paydays for generics manufacturers? Under what circumstances can the effects of this critical factor be muted?
• After Zithromax lost patent protection in the United States, Pfi zer entered the generics market for Zithromax through its own generics subsidiary. How successfully did Pfi zer' s subsidiary fend off erosion of prescription share for Zithromax? What lessons can other drug companies take away from Pfi zer' s strategy?
• Merck employed an unusual pricing strategy in order to retain its market share for Zocor, after generics entered the market for the branded product. How successful was Merck in delaying erosion of Zocor' s market share?
• Oral solids typically experience generics erosion at a different rate than other drug formulations (oral liquids, nasal products, and patches). What factors account for this difference?

Scope

• Methodology: thirteen fi gures and two tables delineating the data of generics erosion for 34 drugs between 2002 and 2006.
• Patterns of generics erosion: rates of erosion for oral solids, oral liquids, and injectables; factors determining rates of erosion; branded products grouped by their erosion rates.
• Exceptions to traditional generics erosion: drugs that did not follow traditional patterns of erosion.
• Outlook: Data from the Centers for Medicare & Medicaid Services (CMS); pending U.S. legislation.

Selection of Brand Products Facing Generic Entry, 2002-2006

• Accupril
• Agrylin
• Axid
• Biaxin
• Celexa
• Cipro
• Difl ucan
• Duragesic
• Effexor
• Flonase
• Floxin/Occufl ox
• Glucophage XR
• Glucotrol XL
• Glucovance
• Lotensin
• Metaglip
• Mobic
• Monopril
• Novantrone
• Paraplatin
• Paxil
• Pravachol
• Proscar
• Retrovir
• Rocephin
• Romazicon
• Tambocor
• Ultram
• Zaditor
• Zestril/Prinivil
• Zithromax
• Zocor
• Zofran
• Zoloft

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Methodology
• Factors Infl uencing Generics Erosion
• Exceptions to Traditional Generics Erosion Patterns
• Patterns of Generics Erosion by Formulation
  • Oral Solids
    • Group 1
    • Group 2
    • Group 3
  • Oral Liquids and Other Formulations (Nasal, Ophthalmic Liquids, Patches/Discs)
  • Injectables
• Other Findings
  • Comparison of Average Oral Solid Generics Erosion
  • Market Infl uence of Generics Manufacturers
  • Price As a Factor
• Will These Patterns Continue?

Tables

• 1. Drugs and Formualtions Examined in this Report
• 2. Defi nitions and Parameters of Drug Groupings in this Report

Figures

• 1. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 1
• 2. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 2
• 3. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 3
• 4. Generics Erosion for Selected Products, 2002-2006: Oral Liquids
• 5. Generics Erosion for Selected Products, 2002-2006: Other Formulations
• 6. Comparison of Average Generics Erosion (by Formulation) for Five Drugs
• 7. Generics Erosion for Selected Products, 2002-2006: Injectables/IVs
• 8. Average Generics Erosion Rates of Oral Solids, 2002-2006
• 9. Estimated Average Number of Generics Competitors by Formulation
• 10. The Effect of Generics Manufacturers on Brand Market Share Volume
• 11. How Brand Manufacturers Can Maintain Total Prescription Share Through Generics Subsidiaries: Zithromax
• 12. How Brand Manufacturers Can Maintain Total Prescription Share Through Generics Subsidiaries: Lotensin
• 13. How Brand Manufacturers Can Maintain Total Prescription Share Through Generics Subsidiaries: Celexa